In Focus: Reagent consistency
How can cell therapy manufacturers guarantee consistent, high-quality results for their final products? In this In Focus feature, we are diving deep into the topic of reagent consistency and the importance of utilizing high-quality ancillary materials during the early stages of your cell therapy development.
In this In Focus feature, learn how manufacturers can utilize the expertise of best-in-class reagent suppliers to ensure their reagents meet quality expectations and limit lot-to-lot variability, to guarantee the best chance at downstream success. Discover the factors that should be considered when scaling your cell therapy up and out in our infographic. Finally, our podcast, featuring experts from Sexton Biotechnologies (now part of BioLife Solutions, WA, USA) and Orbsen Therapeutics (Galway, Ireland) will dive deep into the topic, giving expert insight and advice into the challenges that the industry currently faces.
Infographic
How can we ensure downstream success in cell and gene therapy -When scaling your cell therapy up and out, it’s important to consider several factors from the very start of your research and development journey, to ensure later downstream success. Investing in high-quality ancillary products from trusted suppliers early on in your development process will save you the expensive cost of conversion later down the line.
How and where should I source reagents to ensure consistent and safe final products? View this infographic, produced in association with Sexton Biotechnologies (now part of BioLife Solutions, WA, USA), to discover more about the factors that must be considered and incorporated from the very start of your cell therapy journey.
Podcast
As the cell and gene therapy industry expands further into commercialization, researchers, developers and manufacturers are growing increasingly aware of the need for specialized ancillary materials in the production of therapeutics. High-quality ancillary materials are often neglected during the early stages of development due to perceived cost, but conversion at later stages of development can be prohibitive and detrimental to program success.
In this podcast, in association with Sexton Biotechnologies (now part of BioLife Solutions, WA, USA), Steve Elliman of Orbsen Therapeutics (Galway, Ireland) and Steven Thompson of Sexton Biotechnologies discuss the challenges of variability in producing cell therapeutics, and how using consistent reagents from reliable manufacturers can tackle this challenge. We also dive deep into the importance of gaining and maintaining trustworthy partners early in your cell therapy journey and how this can influence the overall success of your final product.
Resources
Scale up and process development: ask the experts
In association with
